Shares in this article
During Musk’s visit to the company headquarters in Tbingen, participation in CureVac was not discussed, said a spokesman for the biotech company on Thursday. The CureVac main owner and SAP founder Dietmar Hopp had previously rejected speculations about the entrepreneur’s possible entry. Corresponding considerations are “pure fantasy”, Hopp had told the news portal “Merkur.de”. In addition, his promise “that Curevac is and will remain a German company” still applies.
At the same time, Hopp commented positively on a possible collaboration between the company and the Tesla boss. “For CureVac, I can say that there is great potential in the collaboration with Mr. Musk and that a collaboration that goes far beyond vaccines is judged extremely positively.” At his meeting with Federal Economics Minister Peter Altmaier, Musk presented his investment plans, especially for the new plant in Brandenburg, to a person familiar with the conversation. But CureVac was also discussed. Musk and Altmaier agreed that CureVac is “one of the most innovative” companies in the world.
The Tesla subsidiary Grohmann and CureVac are already working together on so-called RNA printers. This production unit for the production of messenger RNA (mRNA), on which the vaccines from CureVac are based, is intended to enable fast delivery on site. CureVac is one of the few German companies that are in the running for a corona vaccine. The EU Commission has concluded exploratory talks with the company about the purchase of up to 405 million vaccine doses. If the study results are positive, CureVac is aiming for approval in the first half of 2021.
Hopp holds around 49 percent of Curevac’s shares through his holding company dievini, while the federal government holds just under 17 percent through the KfW funding bank. In the spring, the US government was also said to be interested in the company, which had gone public on the US technology exchange Nasdaq in mid-August.
Entry of Tesla boss Musk not an issue at meetings with CureVac
CureVac shares temporarily fell 1.79 percent to $ 57.42 in trading on the NASDAQ on Thursday.
Current certificates from
More news about SAP SE
Image sources: Matthias Hangst / Getty Images